Literature DB >> 4652588

Plasma camptothecin (NSC-100880) levels during a 5-day course of treatment: relation to dose and toxicity.

P J Creaven, L M Allen, F M Muggia.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1972        PMID： 4652588

Source DB:  PubMed          Journal:  Cancer Chemother Rep        ISSN： 0069-0112


× No keyword cloud information.
  19 in total

1.  Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in vitro and in vivo.

Authors:  T Tsuruo; T Matsuzaki; M Matsushita; H Saito; T Yokokura
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

Review 2.  Topotecan: a review of its efficacy in small cell lung cancer.

Authors:  D Ormrod; C M Spencer
Journal:  Drugs       Date:  1999-09       Impact factor: 9.546

3.  Factors affecting the in vivo lactone stability and systemic clearance of the lipophilic camptothecin analogue AR-67.

Authors:  Eyob D Adane; Zhiwei Liu; Tian-Xiang Xiang; Bradley D Anderson; Markos Leggas
Journal:  Pharm Res       Date:  2010-04-29       Impact factor: 4.200

Review 4.  New oral chemotherapeutic agents for lung cancer.

Authors:  E M Bengtson; J R Rigas
Journal:  Drugs       Date:  1999       Impact factor: 9.546

5.  CRLX101 (formerly IT-101)-A Novel Nanopharmaceutical of Camptothecin in Clinical Development.

Authors:  Cissy Young; Thomas Schluep; Jungyeon Hwang; Scott Eliasof
Journal:  Curr Bioact Compd       Date:  2011-03

6.  Plasma pharmacokinetics of lactone and carboxylate forms of 20(S)-camptothecin in anesthetized rats.

Authors:  D O Scott; D S Bindra; V J Stella
Journal:  Pharm Res       Date:  1993-10       Impact factor: 4.200

7.  A mechanistic and kinetic study of the E-ring hydrolysis and lactonization of a novel phosphoryloxymethyl prodrug of camptothecin.

Authors:  Bradley A Hanson; Richard L Schowen; Valentino J Stella
Journal:  Pharm Res       Date:  2003-07       Impact factor: 4.200

8.  Antitumor activity of a camptothecin derivative, CPT-11, against human tumor xenografts in nude mice.

Authors:  Y Kawato; T Furuta; M Aonuma; M Yasuoka; T Yokokura; K Matsumoto
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

9.  First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies.

Authors:  Glen J Weiss; Joseph Chao; Jeffrey D Neidhart; Ramesh K Ramanathan; Dawn Bassett; James A Neidhart; Chung Hang J Choi; Warren Chow; Vincent Chung; Stephen J Forman; Edward Garmey; Jungyeon Hwang; D Lynn Kalinoski; Marianna Koczywas; Jeffrey Longmate; Roger J Melton; Robert Morgan; Jamie Oliver; Joanna J Peterkin; John L Ryan; Thomas Schluep; Timothy W Synold; Przemyslaw Twardowski; Mark E Davis; Yun Yen
Journal:  Invest New Drugs       Date:  2013-02-09       Impact factor: 3.850

Review 10.  Tumour-selective targeting of drug metabolizing enzymes to treat metastatic cancer.

Authors:  Monika Wierdl; Lyudmila Tsurkan; M Jason Hatfield; Philip M Potter
Journal:  Br J Pharmacol       Date:  2016-08-22       Impact factor: 8.739
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.